BioTuesdays

Category - Markets

Viralytics

Roth resumes coverage of Viralytics at buy

Roth Capital Partners has resumed coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and AUD$2 price target. The stock closed at AUD$1.05 on Jan. 30. “Based on the clinical efficacy and safety profile of...

Momenta Pharma

Stifel ups Momenta price target to $30

Stifel raised its price target for Momenta Pharmaceuticals (NASDAQ:MNTA) to $30 from $20 after a district court yesterday afternoon ruled that Teva Pharmaceutical’s Copaxone Q3W patents were invalid due to obviousness...

Ocera Therapeutics

Stifel downgrades Ocera Therapeutics to hold

Stifel downgraded Ocera Therapeutics (NASDAQ:OCRX) to “hold” from “buy” and slashed its price target to $1 from $9 after the company reported top-line results from a Phase 2b study evaluating ornithine phenylacetate...

CymaBay Therapeutics

HCW upgrades CymaBay to buy

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on...

Mateon Therapeutics

Maxim starts Mateon at buy

Maxim Group initiated coverage of Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and 12-month price target of $2. The stock was quoted at 42 cents at midday on Jan. 27. Analyst Jason Kolbert writes that...

Adocia

Leerink downgrades Adocia to market perform

Leerink downgraded Adocia (NXT PA:ADOC.FP) to “market perform” and slashed its price target to €15.00 from €82.00 after Eli Lilly terminated its collaboration for Adocia’s ultra-fast insulin product, BioChaperone Lispro...

Athersys Logo

Athersys prices $20-million stock offering

Athersys (NASDAQ:ATHX) priced a public offering of 19,802,000 common shares at a price of $1.01 each for gross proceeds of about $20-million and gave underwriters an option to purchase up to an additional 2,970,300...

Heska-Corporation-Logo

Feltl ups Heska price target to $97

Feltl reiterated a “strong buy” rating for Heska (NASDAQ:HSKA) and raised its price target to $97 from $67 on an increased valuation multiple reflecting Heska’s improved positioning. The stock was quoted at $76.46 near...

ADMA Biologics Logo

Maxim upgrades ADMA Biologics to buy

Maxim Group upgraded ADMA Biologics (NASDAQ:ADMA) to ‘buy” from “hold” and established a price target of $13 after the company agreed to acquire Biotest Pharmaceuticals’ immunoglobulin manufacturing facility in Florida...

Palatin Technologies Logo

Roth resumes coverage of Palatin, AmpliPhi, Pharming

Roth Capital Partners resumed coverage of Palatin Technologies (NYSE MKT: PTN), AmpliPhi Biosciences (NYSE MKT:APHB) and Pharming Group NV (OTC:PHGUF) with “buy” ratings and price targets of $1.50, $3 and €1.50...